Charles River Laboratories Intl. Inc (NYSE:CRL) Director Robert J. Bertolini sold 7,170 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $170.41, for a total value of $1,221,839.70. Following the completion of the transaction, the director now owns 31,905 shares of the company’s stock, valued at $5,436,931.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
CRL stock opened at $176.48 on Friday. Charles River Laboratories Intl. Inc has a 12-month low of $123.17 and a 12-month high of $176.89. The stock has a 50-day moving average price of $157.46 and a two-hundred day moving average price of $141.17. The company has a current ratio of 1.44, a quick ratio of 1.20 and a debt-to-equity ratio of 1.20. The company has a market cap of $8.44 billion, a PE ratio of 34.88, a price-to-earnings-growth ratio of 1.91 and a beta of 1.18.
Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Tuesday, February 11th. The medical research company reported $2.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.83 by $0.18. Charles River Laboratories Intl. had a return on equity of 22.17% and a net margin of 9.61%. The company had revenue of $691.10 million during the quarter, compared to the consensus estimate of $685.46 million. During the same quarter in the prior year, the business earned $1.49 earnings per share. The company’s revenue was up 14.1% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories Intl. Inc will post 7.54 EPS for the current fiscal year.
Several equities analysts recently commented on CRL shares. Bank of America lowered Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 target price for the company. in a research note on Friday, October 18th. Barclays reiterated a “hold” rating and issued a $170.00 target price on shares of Charles River Laboratories Intl. in a research note on Wednesday. Robert W. Baird reiterated an “outperform” rating and issued a $185.00 target price (up from $165.00) on shares of Charles River Laboratories Intl. in a research note on Wednesday. Morgan Stanley boosted their price target on Charles River Laboratories Intl. from $156.00 to $176.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Goldman Sachs Group raised Charles River Laboratories Intl. from a “neutral” rating to a “buy” rating and boosted their price target for the company from $143.00 to $179.00 in a research report on Friday, January 10th. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $169.33.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Read More: What does an equal weight rating mean?
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.